Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study.
Adult
Anemia
/ blood
Antimalarials
/ therapeutic use
Cross-Sectional Studies
Drug Combinations
Educational Status
Female
Ghana
/ epidemiology
Health Knowledge, Attitudes, Practice
Humans
Malaria, Falciparum
/ blood
Odds Ratio
Parasitemia
/ blood
Plasmodium falciparum
/ growth & development
Pregnancy
Pregnancy Complications, Parasitic
/ blood
Prenatal Care
Prevalence
Pyrimethamine
/ therapeutic use
Sample Size
Sulfadoxine
/ therapeutic use
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
09
2020
accepted:
06
04
2021
entrez:
20
4
2021
pubmed:
21
4
2021
medline:
29
9
2021
Statut:
epublish
Résumé
In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy. We assessed the different SP dosage regimen available under the new policy to determine the dose at which women obtained optimal protection against anaemia during pregnancy. A cross-sectional study was conducted among pregnant women who attended antenatal clinic at four different health facilities in Ghana. The register at the facilities served as a sampling frame and simple random sampling was used to select all the study respondents; they were enrolled consecutively as they kept reporting to the facility to receive antenatal care to obtain the required sample size. The haemoglobin level was checked using the Cyanmethemoglobin method. Multivariable logistic regression was performed to generate odds ratios, confidence intervals and p-values. The overall prevalence of anaemia among the pregnant women was 62.6%. Pregnant women who had taken 3 or more doses of IPTp-SP had anaemia prevalence of 54.1% compared to 66.6% of those who had taken one or two doses IPTp-SP. In the multivariable logistic model, primary (aOR 0.61; p = 0.03) and tertiary education (aOR 0.40; p = <0.001) decreased the odds of anaemia in pregnancy. Further, pregnant women who were anaemic at the time of enrollment (aOR 3.32; p = <0.001) to the Antenatal Care clinic and had malaria infection at late gestation (aOR 2.36; p = <0.001) had higher odds of anaemia in pregnancy. Anaemia in pregnancy remains high in the Northern region of Ghana. More than half of the pregnant women were anaemic despite the use of IPTp-SP. Maternal formal education reduced the burden of anaemia in pregnancy. The high prevalence of anaemia in pregnancy amid IPTp-SP use in Northern Ghana needs urgent attention to avert negative maternal and neonatal health outcomes.
Identifiants
pubmed: 33878140
doi: 10.1371/journal.pone.0250350
pii: PONE-D-20-28114
pmc: PMC8057609
doi:
Substances chimiques
Antimalarials
0
Drug Combinations
0
fanasil, pyrimethamine drug combination
37338-39-9
Sulfadoxine
88463U4SM5
Pyrimethamine
Z3614QOX8W
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250350Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Pregnancy Childbirth. 2019 Jul 8;19(1):236
pubmed: 31286878
Malar J. 2020 Jun 24;19(1):222
pubmed: 32580717
Malar J. 2017 Sep 16;16(1):374
pubmed: 28915896
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
J Trop Med. 2020 Nov 23;2020:2325304
pubmed: 33299426
Malar J. 2014 Nov 24;13:455
pubmed: 25421496
Afr Health Sci. 2015 Dec;15(4):1087-96
pubmed: 26958008
Malar J. 2012 Oct 22;11:348
pubmed: 23088844
Clin Infect Dis. 2019 Feb 1;68(4):586-596
pubmed: 29961848
Am J Epidemiol. 2001 Sep 1;154(5):459-65
pubmed: 11532788
Biomed Res Int. 2015;2015:740512
pubmed: 26783526
Malar J. 2007 Nov 08;6:144
pubmed: 17996048
J Vector Borne Dis. 2018 Jul-Sep;55(3):197-202
pubmed: 30618445
Malar J. 2016 Nov 4;15(1):533
pubmed: 27814763
Lancet. 2013 Aug 3;382(9890):372-375
pubmed: 23746778
Afr J Prim Health Care Fam Med. 2019 Apr 10;11(1):e1-e7
pubmed: 31038334
PLoS Med. 2016 Jan 19;13(1):e1001942
pubmed: 26783752
Clin Infect Dis. 2011 Aug 1;53(3):224-30
pubmed: 21765070
Aust Crit Care. 2010 May;23(2):93-7
pubmed: 20347326
J Parasitol Res. 2016;2016:9231946
pubmed: 27042341
PLoS One. 2015 Mar 25;10(3):e0121057
pubmed: 25807235
Malar J. 2018 May 25;17(1):211
pubmed: 29793482
Public Health Nutr. 2012 May;15(5):928-37
pubmed: 22014374
Trans R Soc Trop Med Hyg. 2005 Oct;99(10):739-43
pubmed: 16024057
Perspect Clin Res. 2015 Jul-Sep;6(3):169-70
pubmed: 26229754
Malar J. 2017 Aug 10;16(1):323
pubmed: 28797296
BMC Pregnancy Childbirth. 2019 Dec 11;19(1):495
pubmed: 31829146
Malar J. 2018 Jun 19;17(1):238
pubmed: 29921302
JAMA. 2013 Feb 13;309(6):594-604
pubmed: 23403684
Afr Health Sci. 2015 Sep;15(3):810-8
pubmed: 26957969
PLoS One. 2010 Aug 06;5(8):e12012
pubmed: 20700457
Afr Health Sci. 2005 Dec;5(4):295-9
pubmed: 16615838
Trop Med Int Health. 2014 Sep;19(9):1048-56
pubmed: 24965022
Int J Womens Health. 2010 Aug 09;2:229-33
pubmed: 21072315
Int J Gynaecol Obstet. 2013 May;121(2):103-9
pubmed: 23490427
Malar J. 2015 Nov 05;14:439
pubmed: 26542942
Pan Afr Med J. 2019 Aug 27;33:325
pubmed: 31692871
Malar Res Treat. 2016;2016:1839795
pubmed: 28070444
Trop Med Int Health. 2009 Jun;14(6):688-95
pubmed: 19392740